Fig. 1

High EHMT2 expression is unfavorable for patients with HCC. A EHMT2 expression (mRNA) level in liver hepatocellular carcinoma (LIHC). Data from TCGA (tumor tissues, n = 369; normal tissues, n = 50) and GTEx (normal tissues, n = 160) database were analyzed by GEPIA online tool. TPM, transcripts per million reads. Line, medium; box, interquartile range (IQR); whiskers, non-outlier range; *p < 0.01. B mRNA level of EHMT2 in human specimens was determined by RT-qPCR. n = 31, ***p < 0.001 by paired t-test. C the protein level of EHMT2 in human specimens was determined by Western blot. The bottom section shows the representative of Western blot results. Samples are the same as 1B. NC, adjacent normal controls; Tu, tumors. n = 31. ***p < 0.001 by paired t-test. D EHMT2-based overall and disease-free survival analysis of patients with HCC. In OS and DFS analysis, EHMT2 expression data from TCGA were used, and the median of EHMT2 expression served as the cutoff. High EHMT2, expression level more than median; Low EHMT2, expression level less than the median. A log-rank test was used for the hypothesis test. OS, overall survival analysis; DFS, disease-free survival analysis